Gemtuzumab ozogamicin in acute myeloid leukemia: Past, present and future

Michele Gottardi, Alessandra Sperotto, Andrea Ghelli Luserna Di Rorà, Antonella Padella, Delia Cangini, Maria B. Giannini, Giorgia Simonetti, Giovanni Martinelli, Claudio Cerchione

Research output: Contribution to journalArticlepeer-review

Abstract

after being in the therapeutic wilderness for several decades, acute myeloid leukemia has been recently thrust into the limelight with a series of drug approvals. Technical refinements in production, genetic manipulation and chemical modification of monoclonal antibodies led to growing interest in antibodies-based treatment strategies. Much of the focus of these efforts in acute myeloid leukemia has been on cd33 as a target. On September 2, 2017, the U.S. Food and drug administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory cd33+ acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab ozogamicin, which was the first antibody-drug conjugate approved for human use by the Food and drug administration. in this review we have analyzed the history of this drug which, among several mishaps, is experiencing a second youth and still represents a field to be further explored.
Original languageEnglish
Pages (from-to)395-410
Number of pages16
JournalMinerva Medica
Volume111
Issue number5
DOIs
Publication statusPublished - Oct 2020

Keywords

  • Acute; Gemtuzumab; clinical Trials as topic; Biomarkers
  • Leukemia
  • Myeloid

Fingerprint Dive into the research topics of 'Gemtuzumab ozogamicin in acute myeloid leukemia: Past, present and future'. Together they form a unique fingerprint.

Cite this